Granted Patent
B2
US 12,527,863 · App. 17/393,888 · Granted Jan 20, 2026
Methods for preparing aluminum precipitate compounds for use in therapeutics and vaccines
Inventors:
Robert Schlegl (Siegenfeld, AT); Michael Möhlen (Vienna, AT); Jürgen Heindl-Wruss (Vienna, AT); Michael Weber (Vienna, AT)
Assignee:
Valneva Austria GmbH
A61K39/39A61K38/162A61K38/164A61K39/104A61K39/12C12N7/00A61K39/395A61K2039/525A61K2039/5252A61K2039/55505A61K2039/70C12N2770/24134Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to means and methods for preparing aqueous composition comprising aluminium and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminium content. The invention further relates to aqueous compositions comprising a protein and an aluminium-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
Claims (25)
1 . A method for prolonging a shelf life of an aqueous pharmaceutical composition or vaccine comprising a bacterial protein and an aluminium-salt, said method comprising:
(a) selecting an aluminium-salt that comprises less than 700 ppm heavy metal on the basis of weight with respect to aluminium content; and
(b) combining the selected aluminium-salt with the protein for preparing an aqueous composition or vaccine,
wherein said composition or vaccine comprises less than 350 ppb heavy metal based on the weight of the composition or vaccine, and wherein the aluminium-salt is aluminium hydroxide (Al(OH) 3 ) or aluminium phosphate (AlPO 4 ).
2 . The method according to claim 1 , wherein said heavy metal is selected from the group consisting of Cu, Ni, W, Co, Os, Ru, Cd, Ag, Fe, V, Cr, Pb, Rb, and Mo.
3 . The method according to claim 1 , wherein said heavy metal is selected from Cu or Ni.
4 . The method according to claim 1 , wherein said heavy metal is present in ionic form.
5 . The method according to claim 1 , wherein the aluminium-salt is aluminium hydroxide (Al(OH) 3 ).
6 . The method according to claim 1 , wherein the aqueous composition or vaccine comprises between 5 μg/ml and 50 mg/ml aluminium.
7 . The method according to claim 1 , wherein said aqueous composition or vaccine comprises less than 1.25 ppb Cu, based on the weight of the aqueous composition or vaccine.
8 . The method according to claim 1 , wherein said aqueous composition or vaccine comprises less than 40 ppb Ni based on the weight of the aqueous composition or vaccine.
9 . The method according to claim 1 , wherein said aqueous composition or vaccine comprises between 5 ppb and 250 ppb Fe based on the weight of the aqueous composition or vaccine.
10 . The method according to claim 1 , wherein said bacterial protein is a protein of the Pseudomonas aeruginosa bacterium.
11 . The method according to claim 1 , wherein said aqueous composition or vaccine further comprises a reactive compound selected from the group consisting of a redox active compound, a radical building compound, a stabilizing compound and a combination of any thereof.
12 . The method according to claim 1 , further comprising, before selecting the aluminium-salt that comprises less than 700 ppm heavy metal, obtaining at least two different aluminium-salt preparations.
13 . The method according to claim 12 , further comprising, before selecting the aluminium-salt that comprises less than 700 ppm heavy metal, determining heavy metal contents in said at least two different aluminium-salt preparations.
14 . The method according to claim 1 , wherein said aqueous composition or vaccine is stable for at least one month at 2-8° C.
15 . The method according to claim 1 , wherein
(i) degradation of the protein in said aqueous composition or vaccine is reduced compared to degradation of the protein in a comparative aqueous composition or vaccine; and/or
(ii) storage life of the aqueous composition or vaccine is prolonged compared to storage life of a comparative aqueous composition or vaccine; wherein the comparative aqueous composition or vaccine comprises more than 350 ppb heavy metal based on the weight of the aqueous composition or vaccine.
16 . A method of use of an aluminium salt comprising less than 700 ppm heavy metal on the basis of weight with respect to aluminium content, for (i) counteracting degradation of a protein in an aqueous composition or vaccine; and/or (ii) prolonging storage life of an aqueous composition or vaccine; wherein the aqueous composition or vaccine comprises the protein, a reactive compound and the aluminium-salt, wherein the reactive compound is a redox active compound, a radical building compound, and/or a stabilizing compound, and wherein said protein is a bacterial protein.
17 . The method of use according to claim 16 , wherein
(i) degradation of the protein in the aqueous composition or vaccine is reduced compared to degradation of the protein in a comparative aqueous composition or vaccine; and/or
(ii) storage life of the aqueous composition or vaccine is prolonged compared to storage life of a comparative aqueous composition or vaccine; wherein the comparative aqueous composition or vaccine comprises more than 350 ppb heavy metal based on the weight of the aqueous composition, wherein the comparative aqueous composition or vaccine comprises more than 2.5 ppb Cu.
18 . The method according to claim 13 , wherein said aqueous composition or vaccine further comprises sulphite.
Assignments (7)
AMENDED AND RESTATED PATENT SECURITY AGREEMENT
Recorded Mar 31, 2026
From: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA SWEDEN AB
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 075335/0609 →
RELEASE OF SECURITY INTEREST
Recorded Nov 10, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA USA, INC.
Reel/Frame 073516/0522 →
PATENT SECURITY AGREEMENT
Recorded Oct 20, 2025
From: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA SWEDEN AB
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 073164/0032 →
SECURITY INTEREST
Recorded Jan 19, 2024
From: VALNEVA SE; VALNEVA AUSTRIA GMBH; VALNEVA USA, INC.; VALNEVA SWEDEN AB
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 066182/0174 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 13, 2022
From: SCHLEGL, ROBERT; MOHLEN, MICHAEL; WRUSS, JURGEN; WEBER, MICHAEL
To: INTERCELL AG
Reel/Frame 060182/0945 →
CHANGE OF NAME
Recorded Jun 13, 2022
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 060183/0018 →
ASSET TRANSFER AGREEMENT
Recorded Jun 13, 2022
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 060349/0428 →
Continuity (4)
References Cited (208)
US 2375977A
· Davies et al.
· 1945
[cited by applicant]
US 5545403A
· Page
· 1996
[cited by applicant]
US 5545405A
· Page
· 1996
[cited by applicant]
US 5654403A
· Smith et al.
· 1997
[cited by applicant]
US 5792838A
· Smith et al.
· 1998
[cited by applicant]
US 9884115B2
· Schlegl et al.
· 2018
[cited by applicant]
US 9895437B2
· Schlegl et al.
· 2018
[cited by applicant]
US 9913898B2
· Schlegl et al.
· 2018
[cited by applicant]
US 20040054146A1
· Hellman et al.
· 2004
[cited by applicant]
US 20050158334A1
· Contorni et al.
· 2005
[cited by applicant]
US 20100215580A1
· Hanes et al.
· 2010
[cited by applicant]
US 20110268805A1
· Alexis et al.
· 2011
[cited by applicant]
US 20120027720A1
· Tamiz et al.
· 2012
[cited by applicant]
CN 101734698A
· 2010
[cited by applicant]
EP 1604685A2
· 2005
[cited by applicant]
EP 3106176B1
· 2017
[cited by applicant]
EP 201843083
· 2021
[cited by applicant]
EP 241674134
· 2024
[cited by applicant]
GB 120550A
· 1919
[cited by applicant]
WO WO199814401A1
· 1998
[cited by applicant]
WO WO2009137436A2
· 2009
[cited by applicant]
WO WO2009158284A2
· 2009
[cited by applicant]
WO WO2011075822A1
· 2011
[cited by applicant]
WO WO2013083726A1
· 2013
[cited by applicant]
WO WO2013135274A1
· 2013
[cited by applicant]
WO WO2017109225A1
· 2017
[cited by applicant]
PCT/EP2012/07401, Feb. 18, 2013, International Search Report and Written Opinion.
[cited by applicant]
PCT/EP2012/054387, Oct. 31, 2012, International Search Report and Written Opinion.
[cited by applicant]
GB 1121833.6, Feb. 23, 2012, Combined Search and Examination Report.
[cited by applicant]
GB 1204360.0, May 1, 2012, Combined Search and Examination Report.
[cited by applicant]
EP 20184308.3, Feb. 1, 2021, Extended European Search Report.
[cited by applicant]
Third Party Opposition to EP 3269386 filed by Maiwald GmbH Jun. 13, 2023, transmitted Jun. 20, 2023. 56 pages.
[cited by applicant]
Preliminary Opinion of the Opposition Division in the opposition proceedings against patent EP 3106176 dated May 21, 2019. 9 pages.
[cited by applicant]
Letter from Eric Abadie of European Medicines Agency to Magdalena R. de Zero of European Vaccines Manufacturers dated Dec. 15, 2011. Document D9 filed Jun. 13, 2023 in the opposition proceedings against EP 3269386. 2 pa…
[cited by applicant]
PCT Application No. PCT/EP2012/054387 as filed Mar. 13, 2012. 143 pages.
[cited by applicant]
EP Application No. EP 11192230.8 as filed Dec. 6, 2011. 134 pages.
[cited by applicant]
[No Author Listed], Aluminium Hydroxide, Hydrated, For Adsorption. European Pharmacopoeia 6.0. 2008:1150.
[cited by applicant]
[No Author Listed], European Medicines Agency recommends revaccination for some travellers in need of protection with Ixiaro. European Medicines Agency. May 27, 2011. 2 pages.
[cited by applicant]
[No Author Listed], Experimental Report. Detection of heavy metal content in aluminium salt preparations and aqueous drug compositions. Document D20 filed Nov. 28, 2019 in the opposition proceedings against EP 3106176. …
[cited by applicant]
[No Author Listed], Experimental Report. Influence of Cu content and Alum age on Ixiaro stability. Document D21 filed Nov. 28, 2019 in the opposition proceedings against EP 3106176. 6 pages.
[cited by applicant]
[No Author Listed], FDA Highlights of Prescribing Information. Ixiaro. Intercell AG. 2010. 13 pages.
[cited by applicant]
[No Author Listed], Guidance for Industry. Drug Stability Guidelines. US Department of Health and Human Services, FDA, CVM. Dec. 9, 2008. 51 pages.
[cited by applicant]
[No Author Listed], Guidance for Industry. Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production. US Department of Health and Human Services, FDA, CDER. Oct. 2006. 17 pages.
[cited by applicant]
[No Author Listed], Phosphate-buffered saline (PBS) Chemical Recipe. Cold Spring Harbor Protocols. 2006. Accessed Feb. 8, 2024 as available Feb. 22, 2012 from <https://web.archive.org/web/20120222090621/https://cshproto…
[cited by applicant]
Lin et al., A Functional Epitope Determinant on Domain III of the Japanese Encephalitis Virus Envelope Protein Interacted with Neutralizing-Antibody Combining Sites. J Virol. Feb. 2003;77(4):2600-6. doi: 10.1128/jvi.77.…
[cited by applicant]
Salinas et al., Buffer-dependent fragmentation of a humanized full-length monoclonal antibody. J Pharm Sci. Jul. 2010;99(7):2962-74. doi: 10.1002/jps.22056. Author manuscript, 20 pages.
[cited by applicant]
[No Author Listed] Analysis report on Brenntag aluminum gel 2%—Lot FA353455. 6 pages. Filed in Opposition against EP 3106176 on Jul. 10, 2018. (English translation).
[cited by applicant]
[No Author Listed] Aluminium (hydroxide d') hydrate pour adsorption. European Pharmacopoeia 9.0. Jan. 2017. pp. 1806-1807.
[cited by applicant]
[No Author Listed] Aluminium (hydroxide) hydrated for adsorption. European Pharmacopoeia 9.0. Jan. 2017. pp. 1806-1807. (English translation).
[cited by applicant]
[No Author Listed] Aluminium hydroxide, hydrated, for adsorption. European Pharmacopoeia 6.1. 2008:3395-3396.
[cited by applicant]
[No Author Listed] Aluminium in adsorbed vaccines. European Pharmacopoeia 7.0. 2010:141.
[cited by applicant]
[No Author Listed] Assessment Report for Ixiaro. European Medicines Agency. 2009. 50 pages.
[cited by applicant]
[No Author Listed] Assessment report for Ixiaro. Procedure No. EMEA/H/C/963/A-20/0029. European Medicines Agency. May 25, 2012. 8 pages.
[cited by applicant]
[No Author Listed] Dultavax. Nov. 12, 2010. 7 pages. Filed in Opposition against EP 3106176.
[cited by applicant]
[No Author Listed] Dultavax. Nov. 12, 2010. 7 pages. Filed in Opposition against EP 3106176. (English translation).
[cited by applicant]
[No Author Listed] EPO Acknowledgement of Receipt of documents submitted in Opposition of EP 3106176, dated Jan. 8, 2020. 2 pages.
[cited by applicant]
[No Author Listed] EPO Acknowledgement of Receipt of documents submitted in Opposition of EP 3106176, dated Feb. 10, 2020. 1 page.
[cited by applicant]
[No Author Listed] EPO Preliminary Opinion on Sanofi's Opposition against EP 3106176, dated May 21, 2019. 9 pages.
[cited by applicant]
[No Author Listed] European Medicines Agency (Market Authorisation): Ixiaro® authorised Mar. 31, 2009. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR-Product_Information/human/000963/WC500037287.…
[cited by applicant]
[No Author Listed] Experimental report. Impact of heavy meal (particularly copper) on the potency on a Zika virus vaccine. Filed in Opposition against EP 3106176. Feb. 4, 2019. 3 pages.
[cited by applicant]
[No Author Listed] Filiation SAP du produit fini conditionne vers le produit final vrac du lot de Revaxis/Dultavax G0202-1. Jul. 6, 2018. Filed in Opposition against EP 3106176. 1 page.
[cited by applicant]
[No Author Listed] General Chemical, Rehydragel Adjuvants Product Profile, 2009, pdf pp. 1-2; www.generalchemical.com/assets/pdf/Rehydragel_Adjuvants_Product_Profile.pdf.
[cited by applicant]
[No Author Listed] Ixiaro suspension injectable Vaccin de l'encéphalite japonaise (inactivé, adsorbé). Mar. 2010. 6 pages.
[cited by applicant]
[No Author Listed] Ixiaro suspension for injection. Japanese encephalitis vaccine (inactivated, adsorbed). Mar. 2010. 6 pages. (English translation).
[cited by applicant]
[No Author Listed] Leaflet, Avaxim 80 U Pediatric. Jan. 21, 2010. Filed in Opposition against EP 3106176. 6 pages. (English translation).
[cited by applicant]
[No Author Listed] Methods of Analysis. 2.4.8. Heavy Metals. European Pharmacopoeia 7.0. Jul. 2010. 4 pages.
[cited by applicant]
[No Author Listed] Notice Avaxim 80 U Pediatrique. Jan. 21, 2010. Filed in Opposition against EP 3106176. 6 pages.
[cited by applicant]
[No Author Listed] Opponent Submission prior to Oral Hearing in Opposition of EP 3106176, dated Jan. 8, 2020 by Sanofi Pasteur. 32 pages.
[cited by applicant]
[No Author Listed] Osmium. Interactive Periodic Table. Inorganic Ventures. 2013. 1 page. http://www.inorganicventures.com.
[cited by applicant]
[No Author Listed] Rapport d'analyse du gel d'aluminium Brenntag 2%—Lot FA353455. 6 pages. Filed in Opposition against EP 3106176 on Jul. 10, 2018.
[cited by applicant]
[No Author Listed] Recall of Ixiaro® Vaccine Batch JEV09L37. Jun. 14, 2011. Travel Clinic Blog. 2 pages.
[cited by applicant]
[No Author Listed] Résumé des caractéristiques du produit. Dultavax. Nov. 12, 2010. Filed in Opposition against EP 3106176. 6 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Letter Accompanying Subsequently Filed Items in Opposition of EP 3106176, dated and submitted Jan. 8, 2020. 2 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Letter Accompanying Subsequently Filed Items in Opposition of EP 3106176, dated and submitted Feb. 6, 2020. 2 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Opposition Document No. D22: Rapport D'Essai. Submitted in Opposition of EP 3106176 on Jan. 8, 2020. 6 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Opposition Document No. D23a: Communiqué de Presse, dated Mar. 7, 2013. Submitted in Opposition of EP 3106176 on Jan. 8, 2020. 2 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Opposition Document No. D23b: Extrait du dossier de la demande PCT/EP2012/074701, dont est issu le brevet en cause, dated Sep. 9, 2013. Submitted in Opposition of EP 3106176 on Jan. 8, …
[cited by applicant]
[No Author Listed] Sanofi Pasteur Opposition Document No. D24: WHO Guidelines on Stability Evaluation of Vaccines, adopted Oct. 23-27, 2006. Submitted in Opposition of EP 3106176 on Jan. 8, 2020. 28 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Written Submission in Preparation to/during Oral Proceedings in Opposition of EP 3106176, dated and submitted Feb. 6, 2020. 3 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Written Submission in Preparation to/during Oral Proceedings in Opposition of EP 3106176, dated and submitted Feb. 6, 2020. 4 pages.
[cited by applicant]
[No Author Listed] Sanofi Pasteur Written Submission in Preparation to/during Oral Proceedings in Opposition of EP 3106176. Observations pour le compte de la société Sanofi Pasteur á l'encontre du brevet EP 3 106 176 (E…
[cited by applicant]
[No Author Listed] Summary of Product Characteristics. Dultavax. Nov. 12, 2010. Filed in Opposition against EP 3106176. 6 pages. (English translation).
[cited by applicant]
[No Author Listed] Valneva Auxiliary requests 1-37 in Opposition of EP 3106176. Submitted Jan. 9, 2020. 111 pages.
[cited by applicant]
[No Author Listed] Valneva Auxiliary requests 38-42 in Opposition of EP 3106176. Submitted Feb. 10, 2020. 15 pages.
[cited by applicant]
[No Author Listed] Valneva Letter Accompanying Subsequently Filed Items in Opposition of EP 3106176, dated Feb. 10, 2020. 1 page.
[cited by applicant]
[No Author Listed] Valneva Main Request in Opposition of EP 3106176, dated Jan. 7, 2020. 3 pages.
[cited by applicant]
[No Author Listed] Valneva Opposition Document No. D22: Curriculum vitae of Dr. Robert Schlegl. Submitted in Opposition of EP 3106176 on Jan. 9, 2020. 4 pages.
[cited by applicant]
[No Author Listed] Valneva Opposition Document No. D23: Press Release dated Nov. 28, 2019. Submitted in Opposition of EP 3106176 on Jan. 9, 2020. 2 pages.
[cited by applicant]
[No Author Listed] Valneva Response to the Grounds for Opposition of EP 3106176, dated and submitted Jan. 9, 2020. 18 pages.
[cited by applicant]
[No Author Listed] Valneva Submission in Opposition of EP 3106176, dated Jan. 9, 2020. Submitted Jan. 9, 2020. 2 pages.
[cited by applicant]
[No Author Listed] Valneva Written Submission in Preparation to/during Oral Proceedings in Opposition of EP 3106176, dated Feb. 10, 2020. 6 pages.
[cited by applicant]
[No Author Listed] Williamson Research Centre Wiki. ICP-MS. Modification Date: Aug. 23, 2011. 7 pages. http://wiki.manchester.ac.uk/wrc/index.php/ICP-MS.
[cited by applicant]
[No Author Listed], 2.4.8. Heavy Metals. European Pharmacopoeia, 7th Edition. Jan. 1, 2011; 114-117. Originally published on Jul. 15, 2010.
[cited by applicant]
[No Author Listed], Aluminium Hydroxide Wet Gel, USP. Type: Visco 9. SPI Pharma. Nov. 2010.
[cited by applicant]
[No Author Listed], Aluminum Hydroxide Wet Gel. Type: VAC 20. SPI Pharma. Feb. 2008.
[cited by applicant]
[No Author Listed], Aluminum hydroxide, hydrated, for adsorption. European Pharmacopoeia 7.0 2010:1357-1358.
[cited by applicant]
[No Author Listed], Arsenic. European Pharma. 2010. 7.0; 2.4.2.:113.
[cited by applicant]
[No Author Listed], Assessment report for Ixiaro. European Medicines Agency. May 25, 2012; 8 pages.
[cited by applicant]
[No Author Listed], Diphtheria and pertussis vaccination. WHO technical report series. May 1953; 61:5-88.
[cited by applicant]
[No Author Listed], Iron. European Pharma. 2010. 7.0; 2.4.9.:117.
[cited by applicant]
[No Author Listed], Limit tests-206 aluminum. USP 34. 2011;124-125.
[cited by applicant]
[No Author Listed], Product Specification. Alhydrogel 2%. Statens Serum Institut.
[cited by applicant]
[No Author Listed], Raw material specification: ammonia alum. Issue No. 7. 2011. 1 page.
[cited by applicant]
[No Author Listed], Rehydragel Adjuvants, Product Profile. General Chemical. 2008; pp. 1-2. http://www.generalchemical.com/assets/pdf/Rehydragel_Adjuvants_Product_Profile.pdf [last accessed Oct. 8, 2012].
[cited by applicant]
[No Author Listed], Tentative method of test for nitrite ion in industrial water. ASTM D 1254 53T, 1953;308-309.
[cited by applicant]
[No Author Listed], Vaccines for Human Use. European Pharmacopoeia 7.0. 2010:695-698.
[cited by applicant]
[No Author Listed], Vaccines for Human Use. European Pharmacopoeia 7.6. 2012:4820-4823.
[cited by applicant]
Abadie, Letter re: “Possible effect of high metal ion content in aluminium hydroxide used for the manufacturing of vaccines” sent Dec. 15, 2011. European Medicines Agency.
[cited by applicant]
Abadie, Letter to Executive Director of European Vaccines Manufacturers re: “Use of aluminium hydroxide in the manufacturing process of vaccines—concerns on the possible effect of high metal ion content” sent Dec. 15, 2…
[cited by applicant]
Abadie, Letter to Peter Bachmann re: “Use of aluminium hydroxide in the manufacturing process of vaccines—concerns on the possible effect of high metal ion content” sent Dec. 15, 2011. European Medicines Agency.
[cited by applicant]
Abadie, Letter to regulatory contact person of GlaxoSmithKline Biologicals S.A. re: “Use of aluminium hydroxide in the manufacturing process of vaccines-concerns on the possible effect of high metal ion content” sent De…
[cited by applicant]
[No Author Listed] Agilent 7500 Series ICP-MS. Agilent Technologies. Jun. 21, 2007. 12 pages.
[cited by applicant]
Alipazaga et al., Synergistic effect of Ni(II) and Co(II) ions on the sulfite induced autoxidation of Cu(II)/tetraglycine complex. Dalton Trans. Jul. 7, 2004;(13):2036-40. Epub May 6, 2004.
[cited by applicant]
Auxiliary request 1 for Opposition against EP 3106176. 2 pages. Feb. 4, 2019.
[cited by applicant]
Auxiliary request 2 for Opposition against EP 3106176. 3 pages. Feb. 4, 2019.
[cited by applicant]
Auxiliary request 3 for Opposition against EP 3106176. 3 pages. Feb. 4, 2019.
[cited by applicant]
Auxiliary request 4 for Opposition against EP 3106176. 3 pages. Feb. 4, 2019.
[cited by applicant]
Auxiliary request 5 for Opposition against EP 3106176. 2 pages. Feb. 4, 2019.
[cited by applicant]
Auxiliary request 6 for Opposition against EP 3106176. 2 pages. Feb. 4, 2019.
[cited by applicant]
Auxiliary request 7 for Opposition against EP 3106176. 3 pages. Feb. 4, 2019.
[cited by applicant]
Baylor et al., Aluminum salts in vaccines—US perspective. Vaccine. May 31, 2002;20 Suppl 3: S18-23. Review. Erratum in: Vaccine. Sep. 10, 2002;20(27-28):3428.
[cited by applicant]
Berglund et al., Kinetics and mechanism for manganese-catalyzed oxidation of sulfur (IV) by oxygen in aqueous solution. Inorg Chem. 1993; 32:4527-38.
[cited by applicant]
Brandt et al., Role of chromium and vanadium in the atmospheric oxidation of sulfur (IV). Atmos Environ. 1998;32(4):797-800.
[cited by applicant]
Burnouf et al., A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography. Vox Sang. 1991;60(1):8-15.
[cited by applicant]
Casdorph, EDTA Chelation Therapy: Efficacy in Arteriosclerotic Heart Disease. J Advanc Med. 1989;2:121-129.
[cited by applicant]
Dash et al., Sample treatment approaches for trace level determination of cesium in hepatitis B vaccine by suppressed ion chromatography. Chromatographia. 2012;75(1-2):17-23. Epub Nov. 8, 2011.
[cited by applicant]
Estey et al., Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry. J Pharm Sci. Sep. 2009;98(9):2994-3012. E…
[cited by applicant]
Exley et al., The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. Mar. 2010;31(3):103-9. Epub Feb. 10, 2010.
[cited by applicant]
Grounds for the Opposition against EP 3106176. Sanofi-Pasteur. Cabinet Beau de Lomenie. 24 pages. Jul. 10, 2018.
[cited by applicant]
Grounds for the Opposition against EP 3106176. Sanofi-Pasteur. Cabinet Beau de Lomenie. 24 pages. Jul. 10, 2018. (English translation).
[cited by applicant]
Gupta, Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. Jul. 6, 1998;32(3):155-172.
[cited by applicant]
Huie et al., One-electron redox reaction in aqueous solutions of sulphite with hydroquinone and other hydroxyphenols. J Phys Chem. 1985;89(18):3918-3921.
[cited by applicant]
ICP-MS Agilent Série 7500. Agilent Technologies. Mar. 20, 2007. 12 pages.
[cited by applicant]
Ito et al., Site-specific fragmentation and modification of albumin by sulfite in the presence of metal ions or peroxidase/H2O2: role of sulfate radical. Biochem Biophys Res Commun. May 15, 1991;176(3):1306-12.
[cited by applicant]
Ixiaro®, Annex 1 Summary of Product Characteristics, European Medicines Agency, Ixiaro® pdf, authorized Mar. 31, 2009.
[cited by applicant]
Janosova et al., Determination of selected elements by x-ray fluorescence spectrometry in liquid drug samples after the preconcentration with thioacetamide. (Journal of Analytical Chemistry). 2010;65(1):59-65.
[cited by applicant]
Lambeth et al., The kinetics and mechanism of reduction of electron transfer proteins and other compounds of biological interest by dithionite. J Biol Chem. Sep. 10, 1973;248(17):6095-103.
[cited by applicant]
Letter to Magdalena de Azero from Dr. Eric Abadie of the European Medicines Agency. Dec. 15, 2011. 2 pages.
[cited by applicant]
Li et al., Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng. Dec. 5, 1995;48(5):490-500.
[cited by applicant]
Lima et al., Ruthenium(II) tris(bipyridyl) ion as a luminescent probe for oxygen uptake on the catalyzed oxidation of HSO(3)(−). Talanta. Mar. 4, 2002;56(3):547-56.
[cited by applicant]
Lindblad, Aluminium compounds for use in vaccines. Immunol Cell Biol. Oct. 2004;82(5):497-505.
[cited by applicant]
Main Request for Opposition against EP 3106176. 3 pages. Feb. 4, 2019.
[cited by applicant]
Mayo et al., Protection against oxidative protein damage induced by metal-catalyzed reaction or alkylperoxyl radicals: comparative effects of melatonin and other antioxidants. Biochim Biophys Acta. Mar. 17, 2003;1620(1-…
[cited by applicant]
Miyaki et al., Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations. Vaccine. Mar. 16, 2010;28(13):2505-9.
[cited by applicant]
Mukherjee, “Preparation of adsorbed normal plasma” Haematology. Medical laboratory technology. 2008; 1:386.
[cited by applicant]
Neta et al., Free-radical chemistry of sulfite. Environ Health Perspect. Dec. 1985; 64:209-17.
[cited by applicant]
Notice of Opposition against EP 3106176. Jul. 10, 2018. 8 pages.
[cited by applicant]
Observations of the Proprietor in Response to the Opposition against EP 3106176 by Sanofi Pasteur. Valneva Austria GmbH. 36 pages. Feb. 4, 2019.
[cited by applicant]
PCT/EP2012/074701 Certified copy for opposition. Dec. 20, 2012.
[cited by applicant]
Ph. Eur. Policy on Elemental Impurities—Clarification for Products Outside the Scope of the ICH Q3D Guideline. Aug. 7, 2015. 2 pages.
[cited by applicant]
Ph. Eur. Policy on Elemental Impurities. Apr. 28, 2015. 2 pages.
[cited by applicant]
Poland, The role of sodium bisulfite in the 1996-1997 USA influenza vaccine recall. Vaccine. Nov. 1998; 16(19):1865-8.
[cited by applicant]
Qian et al., Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine. May 12, 2008;26(20):2521-7. Epub Mar. 27, 2008.
[cited by applicant]
Qian et al., Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Vaccine. May 16, 2007;25(20):3923-33. Epub Mar. 13, 2007.
[cited by applicant]
Ranguelova et al., (Bi)sulfite oxidation by copper, zinc-superoxide dismutase: Sulfite-derived, radical-initiated protein radical formation. Environ Health Perspect. Jul. 2010;118(7):970-5. Epub Mar. 26, 2010.
[cited by applicant]
Reemers et al., Reduced immune reaction prevents immunopathology after challenge with avian influenza virus: a transcriptomics analysis of adjuvanted vaccines. Vaccine. Aug. 31, 2010;28(38):6351-60.
[cited by applicant]
Response to communication pursuant Rule 70(2) and 70a(2) EPC EP 16183076.5. Feb. 6, 2017. 2 pages.
[cited by applicant]
Richardson, Letter to Grant Castle re: “Access to documents held by the European Medicines Agency” sent Jan. 24, 2013. European Medicines Agency.
[cited by applicant]
Romero, Specification for Rehydragel® CG Aluminum Hydroxide Compressed Gel. General Chemical Standard Operating Procedure. Jul. 14, 2011; 2 pages.
[cited by applicant]
Sanofi Pasteur. Bill of Sale. Mar. 31, 2011. Filed in Opposition against EP 3106176.
[cited by applicant]
Schlegl et al., Influence of elemental impurities in aluminum hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, Ixiaro(®). Vaccine. Nov. 4, 2015;33(44):5989-96. doi: 10.1016/j.vaccine.201…
[cited by applicant]
Scott, Formulation Development—Making the Medicine. BioProcess International. 2006:42-56.
[cited by applicant]
Shi, Generation of SO3.- and OH radicals in SO3(2-) reactions with inorganic environmental pollutants and its implications to SO3(2-) toxicity. J Inorg Biochem. Nov. 15, 1994;56(3):155-65.
[cited by applicant]
Soysal et al., Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey. Eur J Pediatr. Jun. 2007;166(6):533-9.
[cited by applicant]
Srivastava et al., A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine. Aug. 14, 2001;19(31):4557-65.
[cited by applicant]
Stadtman, Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radic Biol Med. 1990;9(4):315-25.
[cited by applicant]
Stewart-Tull, Harmful and Beneficial Activities of Immunological Adjuvants. In: Vaccine Adjuvants. Preparation methods and research protocols. O'Hagan, Ed. 2000;42:29-63.
[cited by applicant]
Trouvin, Letter to EDQM-Council of Europe re: “Use of aluminium hydroxide in the manufacturing process of vaccines—concerns on the possible effect of high metal ion content” sent Jul. 11, 2012. European Medicines Agency.
[cited by applicant]
Trouvin, Letter to EDQM-Council of Europe re: “Use of aluminium hydroxide in the manufacturing process of vaccines—concerns on the possible effect of high metal ion content” sent Mar. 7, 2012. European Medicines Agency.
[cited by applicant]
Wittayanukulluk et al., Effect of microenvironment pH of aluminum hydroxide adjuvant on the chemical stability of adsorbed antigen. Vaccine. Mar. 12, 2004;22(9-10):1172-6.
[cited by applicant]
Wolthers, Letter to C. Vielle, Secretariat of the European Pharmacopoeia Commission re: Request for revision of monograph. Aluminum hydroxide, hydrated, for adsorption. 7th Ed., sent on Mar. 14, 2013.
[cited by applicant]
World Health Organization “WHO”, Annex 1 Guidelines for the production and quality control of synthetic peptide vaccines. 1999. WHO Technical Report Series, No. 889.
[cited by applicant]
World Health Organization, Temperature Sensitivity of Vaccines, WHO Press, Department of Immunization, Vaccines and Biologicals. Aug. 2006. pp. 1-62.
[cited by applicant]
Preliminary Opinion of the Board of Appeal dated Nov. 12, 2021, in the Appeal Proceedings T1684/20 of the revoked parent Patent EP3106176. 13 pages.
[cited by applicant]
Response dated Nov. 27, 2023, from Valneva Austria GmbH to Opponent, in European Patent No. EP3269386. 72 pages.
[cited by applicant]
Response dated Mar. 20, 2024, from Opponent to Valneva Austria GmbH, in European Patent No. EP3269386. 32 pages.
[cited by applicant]
Response dated Apr. 29, 2024, from Valneva Austria GmbH to Opponent, in European Patent No. EP3269386. 11 pages.
[cited by applicant]
[No Author Listed], Experimental Report. Impact of heavy metal (Cu) content on stability of Zika virus vaccine. Document D21 filed Nov. 27, 2023, in the opposition proceedings against EP3269386. 3 pages.
[cited by applicant]
[No Author Listed], Influence of Cu content and Alum age on Ixiaro stability. Document D23 filed Nov. 27, 2023, in the opposition proceedings against EP3269386. 7 pages.
[cited by applicant]
[No Author Listed], Valneva Announces EMA Approval of Ixiaro® Shelf Life Extension to 36 Months. Valneva SE Press Release dated Nov. 28, 2019. Document D24 filed Nov. 27, 2023, in the opposition proceedings against EP32…
[cited by applicant]
[No Author Listed], Monograph 214: Poliomyelitis vaccine (inactivated). In: European Pharmacopoeia, Fourth Edition. Sep. 20, 2001. Document D25 filed Mar. 20, 2024, in the opposition proceedings against EP3269386. 5 pag…
[cited by applicant]
[No Author Listed], Ixiaro—Procedural step taken and scientific information after the authorisation. European Medicines Agency. Retrieved from <https://www.ema.europa.eu/en/documents/procedural-steps-after/ixiaro-epar-p…
[cited by applicant]
[No Author Listed], Tables 1-6 summarizing the passages of P1 cited by the Patentee and showing relevant claim features which are missing in the cited passages. Document D28 filed Mar. 20, 2024 in the opposition proceed…
[cited by applicant]
[No Author Listed], Tables 1-19 summarizing the passages of the application as filed (17185526.5) cited by the Patentee and showing relevant claim features which are missing in the cited passages. Document D29 filed Mar…
[cited by applicant]
[No Author Listed], Claim requests filed in the appeal proceedings T1684/20 of the revoked parent patent EP3106176B1. Document D30 filed Mar. 20, 2024 in the opposition proceedings against EP3269386. 138 pages.
[cited by applicant]
Doel et al., The evaluation of a physical method for the quantification of inactivated poliovirus particles and its relationship to D-antigenicity and potency testing in rats. J Biol Stand. Jan. 1984;12(1):93-9. doi: 10…
[cited by applicant]
Communication of a notice of opposition issued in EP Patent No. EP3785730 on Jan. 29, 2025. 31 pages.
[cited by applicant]
Communication of the Board of Appeal pursuant to Article 15(1) of the Rules of Procedure of the Boards of Appeal. Issued on Nov. 12, 2021 in Opposition No. OP3029EP00 against EP Patent No. EP 3106176. 13 pages. D09 on E…
[cited by applicant]
European Medicines Agency, Use of aluminium hydroxide in the manufacturing process of vaccines—concerns on the possible effect of high metal ion content. Dec. 15, 2011. 2 pages. D04 on Evidence presented opposition docu…
[cited by applicant]
Lin et al., A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interacted with neutralizing-antibody combining sites. J Virol. Feb. 2003;77(4):2600-6. doi: 10.1128/jvi.77.…
[cited by applicant]
No Author Listed, Aluminium Hydroxide, Hydrated, for Adsorption. Monograph 1664 from European Pharmacopoeia 11.0. Jan. 2017. 2 pages. D06 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan…
[cited by applicant]
No Author Listed, Aluminium Hydroxide, Hydrated, for Adsorption. Monograph 1664 from European Pharmacopoeia 7.0. Apr. 2008. 2 pages. D11 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan.…
[cited by applicant]
No Author Listed, Aluminium Phosphate Hydrate. Monograph 1598 from European Pharmacopoeia 11.6. Jan. 2025. 1 page. D07 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 2025.
[cited by applicant]
No Author Listed, Dultavax, suspension injectable en seringue preremplie. Vaccin diphterique, tetanique et poliomyelitique (inactive), (adsorbe). Nov. 12, 2010. 1 page. D13-2 on Evidence presented opposition document fo…
[cited by applicant]
No Author Listed, Filiation SAP du Produit Fini Conditionne vers le Produit Final Vrac du lot de Revaxis/Dultavax. 1 page. D13-4 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 202…
[cited by applicant]
No Author Listed, Invoices Concerning Lot G0202-1 of Dultavax. Apr. 2011 and May 2011. 1 page. D13-3 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 2025.
[cited by applicant]
No Author Listed, Rapport D'Analyse Du Gel d'Aluminium Brenntag 2% - Lot FA353455. 1 page. D13-5 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 2025.
[cited by applicant]
No Author Listed, Rapport D'Analyse Du Gel d'Aluminium Brenntag 2% - Lot FA353455. 6 pages. D13 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 2025.
[cited by applicant]
No Author Listed, Resume Des Caracteristiques du Produit. Nov. 12, 2010. 6 pages. D13-1 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 2025.
[cited by applicant]
No Author Listed, Vaccines for Human Use. Monograph 0153 from European Pharmacopoeia 11.0. Apr. 2022. 4 pages. D08 on Evidence presented opposition document for Patent No. EP3785730, submitted Jan. 29, 2025.
[cited by applicant]
Patel et al., Stability Considerations for Biopharmaceuticals, Part 1. Overview of Protein and Peptide Degradation Pathways. BioProcess International. Jan. 2011. 10 pages. D16 on Evidence presented opposition document f…
[cited by applicant]
Vinatier, Email exchange between J. Vinatier and F. Niemann regarding MEA/CHMP/971225/2011 Request for Information. Jan. 8, 2025. 4 pages. D05 on Evidence presented opposition document for Patent No. EP3785730, submitte…
[cited by applicant]